Brainstorm Cell Therapeutics (BCLI)

• Market cap: $5.99M
• 1 day: 5.98%
• 5 days: 6.67%
• 1 month: -32.29%
• 3 months: -51.97%
• 6 months: -50.26%
• Year to date: -54.44%
• 1 year: -87.78%
• 5 years: -98.93%
• 10 years: -98.43%
• Sector: Healthcare
• Industry: Biotechnology

About: Brainstorm Cell Therapeutics Inc is a biotechnology company. The company is developing novel adult stem cell therapies for debilitating neurodegenerative disorders such as Amyotrophic Lateral Sclerosis (ALS, also known as Lou Gehrig's disease), Progressive Multiple Sclerosis (PMS), and Parkinson's disease (PD). Brainstorm's NurOwn, its proprietary process for the propagation of Mesenchymal Stem Cells (MSC) and differentiation into neurotrophic factor-(NTF) secreting cells (MSC-NTF), and their transplantation at, or near, the site of damage, offers the hope of more effectively treating neurodegenerative diseases.

Employees: 27

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

6.53% less ownership

Funds ownership: 13.77% [Q3] → 7.24% (-6.53%) [Q4]

11% less funds holding

Funds holding: 38 [Q3] → 34 (-4) [Q4]

18% less first-time investments, than exits

New positions opened: 14 | Existing positions closed: 17

78% less capital invested

Capital invested by funds: $2.52M [Q3] → $558K (-$1.96M) [Q4]

94% less repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 18